243 related articles for article (PubMed ID: 37541751)
21. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.
Suchorska B; Jansen NL; Linn J; Kretzschmar H; Janssen H; Eigenbrod S; Simon M; Pöpperl G; Kreth FW; la Fougere C; Weller M; Tonn JC;
Neurology; 2015 Feb; 84(7):710-9. PubMed ID: 25609769
[TBL] [Abstract][Full Text] [Related]
22. Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.
Kebir S; Khurshid Z; Gaertner FC; Essler M; Hattingen E; Fimmers R; Scheffler B; Herrlinger U; Bundschuh RA; Glas M
Oncotarget; 2017 Jan; 8(5):8294-8304. PubMed ID: 28030820
[TBL] [Abstract][Full Text] [Related]
23. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
[TBL] [Abstract][Full Text] [Related]
24. The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment.
Mehrkens JH; Pöpperl G; Rachinger W; Herms J; Seelos K; Tatsch K; Tonn JC; Kreth FW
J Neurooncol; 2008 May; 88(1):27-35. PubMed ID: 18217207
[TBL] [Abstract][Full Text] [Related]
25. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic yield of simultaneous dynamic contrast-enhanced magnetic resonance perfusion measurements and [
Henriksen OM; Hansen AE; Muhic A; Marner L; Madsen K; Møller S; Hasselbalch B; Lundemann MJ; Scheie D; Skjøth-Rasmussen J; Poulsen HS; Larsen VA; Larsson HBW; Law I
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4677-4691. PubMed ID: 35907033
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.
Poulsen SH; Urup T; Grunnet K; Christensen IJ; Larsen VA; Jensen ML; Af Rosenschöld PM; Poulsen HS; Law I
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):373-381. PubMed ID: 27554774
[TBL] [Abstract][Full Text] [Related]
28. O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma.
Pöpperl G; Goldbrunner R; Gildehaus FJ; Kreth FW; Tanner P; Holtmannspötter M; Tonn JC; Tatsch K
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1018-25. PubMed ID: 15877226
[TBL] [Abstract][Full Text] [Related]
29. Patterns of failure for patients with glioblastoma following O-(2-[
Lundemann M; Costa JC; Law I; Engelholm SA; Muhic A; Poulsen HS; Munck Af Rosenschold P
Radiother Oncol; 2017 Mar; 122(3):380-386. PubMed ID: 28110959
[TBL] [Abstract][Full Text] [Related]
30. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
31. Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET.
Kertels O; Mihovilovic MI; Linsenmann T; Kessler AF; Tran-Gia J; Kircher M; Brumberg J; Monoranu CM; Samnick S; Ernestus RI; Löhr M; Meyer PT; Lapa C
Clin Nucl Med; 2019 Sep; 44(9):695-701. PubMed ID: 31274552
[TBL] [Abstract][Full Text] [Related]
32. Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.
Hayes AR; Jayamanne D; Hsiao E; Schembri GP; Bailey DL; Roach PJ; Khasraw M; Newey A; Wheeler HR; Back M
Pract Radiat Oncol; 2018; 8(4):230-238. PubMed ID: 29730279
[TBL] [Abstract][Full Text] [Related]
33. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
[TBL] [Abstract][Full Text] [Related]
34. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
Galldiks N; Dunkl V; Ceccon G; Tscherpel C; Stoffels G; Law I; Henriksen OM; Muhic A; Poulsen HS; Steger J; Bauer EK; Lohmann P; Schmidt M; Shah NJ; Fink GR; Langen KJ
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2377-2386. PubMed ID: 29982845
[TBL] [Abstract][Full Text] [Related]
35. Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience.
Ceccon G; Lazaridis L; Stoffels G; Rapp M; Weber M; Blau T; Lohmann P; Kebir S; Herrmann K; Fink GR; Langen KJ; Glas M; Galldiks N
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1626-1635. PubMed ID: 29564490
[TBL] [Abstract][Full Text] [Related]
36. Margin reduction in radiotherapy for glioblastoma through
Fleischmann DF; Unterrainer M; Schön R; Corradini S; Maihöfer C; Bartenstein P; Belka C; Albert NL; Niyazi M
Radiother Oncol; 2020 Apr; 145():49-55. PubMed ID: 31923709
[TBL] [Abstract][Full Text] [Related]
37. Functional brain imaging: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(22):1-79. PubMed ID: 23074493
[TBL] [Abstract][Full Text] [Related]
38. Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.
Brahm CG; den Hollander MW; Enting RH; de Groot JC; Solouki AM; den Dunnen WFA; Heesters MAAM; Wagemakers M; Verheul HMW; de Vries EGE; Pruim J; Walenkamp AME
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2404-2412. PubMed ID: 30032322
[TBL] [Abstract][Full Text] [Related]
39. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
Kebir S; Fimmers R; Galldiks N; Schäfer N; Mack F; Schaub C; Stuplich M; Niessen M; Tzaridis T; Simon M; Stoffels G; Langen KJ; Scheffler B; Glas M; Herrlinger U
Clin Cancer Res; 2016 May; 22(9):2190-6. PubMed ID: 26673798
[TBL] [Abstract][Full Text] [Related]
40. Comparison of O-(2-
Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
World Neurosurg; 2018 May; 113():e727-e737. PubMed ID: 29510293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]